Navigation Links
Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling
Date:12/31/2007

A new study by Cambridge University reveals that doctors treating life-threatening emergencies such as allergy attacks may give the wrong dosage of adrenaline (epinephrine) because of confusing labelling.

Adrenaline is stored in salt water in glass ampoules which are broken open when the drug is needed. The amount of adrenaline contained in the ampoule is usually expressed as both a dose (1 mg of the drug per 1 mL of salt water) and a ratio (1 part drug for every 1000 parts of salt water) on the label.

The ratio requires doing arithmetic to figure out how much drug to give. Therefore, doctors understand doses much better (and quicker) than ratios. Dr Daniel Wheeler at the University of Cambridge concluded from his research that having to do extra calculations to figure out how much adrenaline to give a person in an emergency might lead to the errors and delays which are common in administering the drug.

Dr Wheeler said: It is well documented that patients are commonly given the wrong dosage of adrenaline.

In order to determine whether the labelling was indeed the cause of the high number of dosing errors, the researchers set up mock scenarios. They programmed a medical mannequin to look like it was having a life-threatening allergic reaction. They then gave the doctors ampoules of adrenaline and told them to treat the emergency.

One half of the doctors were randomly assigned to ampoules with labels that had the adrenaline dose. The other half were randomly assigned to ampoules with labels that had the amount of adrenaline expressed as a ratio. The researchers then measured the amount of drug the doctors gave and how long it took them to give it.

All but 2 doctors out of 14 whose ampoules with labels that expressed the amount of adrenaline as a ratio overdosed their patients. Because they had to figure out how much drug to give, the doctors using ampoules labeled with a ratio also took about 1.5 minutes longer to give it.

The findings might be different if the doctors had to treat a real person. In reality, the labels have doses and ratios, not one or the other, said Dr Wheeler. However, this does give us insight into the problem and a fairly easy solution expressing drug concentrations exclusively as doses we believe would improve patient safety.


'/>"/>
Contact: Dr Daniel Wheeler
dww21@cam.ac.uk
44-019-542-11971
University of Cambridge
Source:Eurekalert

Related biology news :

1. Doctors learn to control their own brains pain responses to better treat patients
2. Drug dosages often incorrect for obese patients
3. Triage study challenges notions of emergency medical response to disaster
4. Human embryonic stem cells remain embryonic because of epigenetic factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
Breaking Biology Technology: